Summary
The effects of the new GABAB antagonist, CGP 35348 (3-aminopropane-diethoxymethylphosphinic acid), on rat striatal dopamine synthesis and the increases thereof, caused by (−)-baclofen, γ-butyrolactone (GBL), and HA 966 (3-amino-l-hydroxypyrrolid-2-one), were investigated. CGP 35348 did not alter dopamine synthesis on its own up to the highest dose tested (500 mg/kg i.p.). However, it antagonized the increase elicited by 50 mg/kg s. c. (−)-baclofen at doses above 100 mg/kg i. p.; at 500 mg/kg i. p. this antagonism disappeared within about 6 h of interval between the administration of the compound and (−)-baclofen. CGP 35348 also clearly and significantly attenuated the effects of graded doses of GBL and HA 966 at 500 mg/kg i. p., but was unable to alter the responses elicited by 0.3 mg/kg i. p. haloperidol or 10 mg/kg i. p. tetrabenazine. This indicates that the compound did not generally attenuate increases of dopamine synthesis. It is likely that its GABAB antagonistic properties are responsible for the attenuation of the effect of (−)-baclofen, and our results suggest that this compound is useful for the characterization of the role of GABAB receptors in vivo, e.g. in behaviour. On the other hand, they also suggest the possibility that GBL and HA 966 elicit their effects on dopamine synthesis by means of an interaction with GABAB receptors; a weak in vitro interaction with the latter in radioligand binding experiments has been found for GBL, but not for HA 966.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Anden N-E, Wachtel H (1977) Biochemical effects of baclofen (p-chlorophenyl-GABA) on the dopamine and the noradrenaline in the rat brain. Acta Pharmacol Toxicol 40:310–320
Bartholini G (1985) GABA receptor agonists: pharmacological spectrum and therapeutic actions. Med Res Rev 5:55–75
Benavides J, Rumigny JF, Bourguignon JJ, Cash C, Wermuth CG, Mandel P, Maitre M (1982) High affinity binding site for γ-hydroxybutyric acid in rat brain. Life Sci 30:953–961
Bittiger H, Fröstl W, Hauser K, Karlsson G, Klebs K, Olpe HR, Pozza M, Radeke E, Steinmann M, Van Riezen H, Vassout A (1990) Biochemistry, electrophysiology and pharmacology of a new GABAB antagonist. In: Bowery NG, Bittiger H, Olpe HR (eds), GABAB receptors in mammalian function. Proceedings of the 1st International GABAB Symposium (Cambridge, UK, September 1989). Wiley & Sons Ltd., Chichester, pp 47–60
Bonta IL, De Vos CJ, Grijsen H, Hillen FC, Noach EL, Sim AW (1971) 1-Hydroxy-3-amino-pyrrolidone-2 (HA-966): a new GABA-like compound, with potential use in extrapyramidal diseases. Br J Pharmacol 43:514–535
Bowery N (1989) GABAB receptors and their significance in mammalian pharmacology. TIPS 10:401–407
Bowery NG, Hill DR, Hudson AL, Doble A, Middlemiss DN, Shaw J, Turnbull M (1980) (−)-Baclofen decreases neurotransmitter release in the mammalian CNS by an action at a novel GABA receptor. Nature 283:92–94
Carlsson A, Lindqvist M (1973) In vivo measurements of tryptophan and tyrosine hydroxylase activities in mouse brain. J Neural Transm 34:79–91
Cott J, Carlsson A, Engel J, Lindqvist M (1976) Suppression of ethanol-induced locomotor stimulation by GABA-like drugs. Naunyn-Schmiedeberg's Arch Pharmacol 295:203–209
Da Prada M, Keller HH (1976) Baclofen and γ-hydroxybutyrate: similar effects on cerebral dopamine neurones. Life Sci 19:1253–1263
Gessa GL, Vargiu L, Crabai F, Boero GC, Caboni F, Camba R (1966) Selective increase of brain dopamine induced by γ-hydroxybutyrate. Life Sci 5:1921–1930
Kerr DJ, Ong J, Prager RH, Gynther BD, Curtis DR (1987) Phaclofen: a peripheral and central baclofen antagonist. Brain Res 405:150–154
Nowycky MC, Roth RH (1978) Dopaminergic neurons: role of presynaptic receptors in the regulation of transmitter biosynthesis. Progr Neuro-Psychopharmacol Biol Psychiat 2:139–158
Olpe HR, Karlsson G, Pozza MF, Brugger F, Steinmann M, Van Riezen H, Fagg G, Hall RG, Froestl W, Bittiger H (1990) CGP 35348: a centrally active blocker of GABAB receptors. Eur J Pharmacol 187:27–38
Singh L, Donald AE, Foster AC, Hutson PH, Iversen LL, Iversen SD, Kemp JA, Leeson PD, Marshall GR, Oles RJ, Priestley T, Thorn L, Tricklebank MD, Vass CA, Williams BJ (1990) Enantiomers of HA-966 (3-amino-l-hydroxypyrrolid-2-one) exhibit distinct central nervous system effects: (+)-HA-966 is a selective glycine/N-methyl-D-aspartate receptor antagonist, but (−)-HA-966 is a potent γ-butyrolactone-like selective. Proc Natl Acad Sci USA 87:347–351
Snead OC, Liu CC (1984) Gamma-hydroxybutyric acid binding sites in rat and human brain synaptosomal membranes. Biochem Pharmacol 33:2587–2590
Stock G, Magnusson T, Anden N-E (1973) Increase in brain dopamine after axotomy or treatment with gammahydroxybutyric acid due to elimination of the nerve impulse flow. Naunyn-Schmiedeberg's Arch Pharmacol 278:347–361
Waldmeier PC (1990) Weak impact of GABA uptake inhibition on nigrostriatal dopamine function. Biogenic Amines 7:603–611
Waldmeier PC, Baumann PA (1990) Presynaptic GABA receptors. Ann NY Acad Sci 604:136–151
Waldmeier PC, Maitre L (1978) Effects of baclofen on dopamine metabolism and interaction with neuroleptic effects. Eur J Pharmacol 47:191–200
Waldmeier PC, Huber H, Heinrich M, Stoecklin K (1985) Discrimination of neuroleptics by means of their interaction with amfonelic acid: an attempt to characterize the test. Biochem Pharmacol 34:39–44
Walters JR, Roth RH (1972) Effect of γ-hydroxybutyrate on dopamine and dopamine metabolism in the rat striatum. Biochem Pharmacol 21:2111–2121
Walters JR, Roth RH (1976) Dopaminergic neurons: An in vivo system for measuring drug interactions with presynaptic receptors. Naunyn-Schmiedeberg's Arch Pharmacol 296:5–14
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Waldmeier, P.C. The GABAB antagonist, CGP 35348, antagonizes the effects of baclofen, γ-butyrolactone and HA 966 on rat striatal dopamine synthesis. Naunyn-Schmiedeberg's Arch Pharmacol 343, 173–178 (1991). https://doi.org/10.1007/BF00168606
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00168606